参考文献/References:
[1]Zhang Y,Hunter T.Roles of Chk1 in cell biology and cancer therapy[J].Int J Cancer,2014,134(5):1013-1023.
[2]Walker M,Black EJ,Oehler V,et al.Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity[J].Oncogene,2009,28(24):2314-2323.
[3]Walworth N,Davey S,Beach D.Fission yeast chkl protein kinase links the rad checkpoint pathway to cdc2[J].Nature,1993,363(6427):368-371.
[4]Furuya K.DNA checkpoints in fission yeast[J].Journal of Cell Science,2003,116(19):3847-3848.
[5]Shimuta K,Nakajo N,Uto K,et al.Chk1 is activated transiently and targets Cdc25A for degradation at the Xenopus midblastula transition[J].The EMBO J,2001,21(14):3694-3703.
[6]Collart C,Smith JC,Zegerman P.Chk1 Inhibition of the Replication Factor Drf1 Guarantees Cell-Cycle Elongation at the Xenopus laevis Mid-blastula Transition[J].Developmental Cell,2017,42(1):82-96.
[7]Smith J,Larue L,Gillespie DA.Chk1 is essential for the development of murine epidermal melanocytes[J].Pigment Cell Melanoma Res,2013,26(4):580-585.
[8]Lunardi A,Varmeh S,Chen M,et al.Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis[J].Cancer Discovery,2015,5(5):550-563.
[9]Yuan R,Vos HR,Van RE,et al.Chk1 and 14-3-3 proteins inhibit atypical E2Fs to prevent a permanent cell cycle arrest[J].Embo Journal,2018,37(5):1-17.
[10]O'Connor MJ.Targeting the DNA Damage Response in Cancer[J].Molecular Cell,2015,60(4):547-560.
[11]Liu Y,Vidanes G,Lin YC,et al.Characterization of a Saccharomyces cerevisiae homologue of Schizosaccharomyces pombe Chk1 involved in DNA-damage-induced M-phase arrest[J].Mol Gen Genet,2000,262(6):1132-1146.
[12]Lam MH,Liu Q,Elledge SJ,et al.Chk1 is haploinsufficient for multiple functions critical to tumor suppression[J].Cancer Cell,2004,6(1):45-59.
[13]Signore M,Buccarelli M,Pilozzi E,et al.UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response[J].Oncotarget,2016,7(28):44113-44128.
[14]Lien WC,Chen TY,Sheu SY,et al.7-hydroxy-staurosporine,UCN-01,induces DNA damage response, and autophagy in human osteosarcoma U2-OS cells[J].Journal of Cellular Biochemistry,2018,119(6):4729-4741
[15]Luqi W,Yue W,Andy C,et al.Effects of a checkpoint kinase inhibitor,AZD7762,on tumor suppression and bone remodeling[J].International Journal of Oncology,2018,53(3):1001-1012.
[16]Park YH,Kim DK,Kim HW,et al.Repositioning of anti-cancer drug candidate,AZD7762,to an anti-allergic drug suppressing IgE-mediated mast cells and allergic responses via the inhibition of Lyn and Fyn[J].Biochem Pharmac,2018,154(1):270-277.
[17]Suzuki M,Yamamori T,Bo T,et al.MK-8776,a novel Chk1 inhibitor,exhibits an improved radiosensitizing effect compared to UCN-01 by exacerbating radiation-induced aberrant mitosis[J].Translational Oncology,2017,10(4):491-500.
[18]Laquente B,Lopez-Martin J,Richards D,et al.A phase Ⅱ study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients[J].BMC Cancer,2017,17(1):137-146.
[19]Wayne J,Brooks T,Massey AJ.Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase[J].Oncotarget,2016,7(51):85033-85048.
[20]Walton MI,Eve PD,Hayes A,et al.The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma[J].Oncotarget,2016,7(3):2329-2342.
[21]Larocheclary A,Lucchesi C,Rey C,et al.CHK1 Inhibition in Soft-Tissue Sarcomas:Biological and Clinical Implications[J].Annals of Oncology Official Journal of the European Society for Medical Oncology,2018,29(4):1023-1029.
[22]Tullio AD,Rouault-Pierre K,Abarrategi A,et al.The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia[J].Nature Communications,2017,8(1):1679.
[23]Wayne J,Stokes S,Foloppe N,et al.Identification and preclinical characterisation of VER-250840,a potent,selective Chk1 inhibitor with in vivo oral single-agent antitumor activity [J].Molecular Targets and Cancer Therapeutics,2018,17(1):Abstract nr B163.
[24]Deraska P,Reavis H,Labe S,et al.Whole-genome CRISPR/Cas9 screen of the CHK1 inhibitor prexasertib implicates FAM122A loss as a potential resistance mechanism[J].AACR Cancer Res,2018,78(13):4287.
[25]Patel R,Barker HE,Kyula J,et al.An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation[J].Radiotherapy and Oncology,2017,122(3):470-475.
[26]Zhou ZR,Yang ZZ,Wang SJ,et al.The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy[J].Acta Pharmacol Sin,2017,38(4):513-523.
[27]Nie C,Luo Y,Zhao X,et al.Caspase-9 mediates Puma activation in UCN-01-induced apoptosis[J].Cell Death and Disease,2014,5(10):e1495.
[28]Wang FZ,Fei HR,Cui YJ,et al.The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest,DNA damage response and autophagy in cancer cells[J].Apoptosis,2014,19(9):1389-1398.
[29]Zhang Y,Lai J,Du Z,et al.Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress[J].Oncotarget,2016,7(23):34688-34702.
[30]Suzuki M,Yamamori T,Bo T,et al.MK-8776,a novel Chk1 inhibitor,exhibits an improved radiosensitizing effect compared to UCN-01 by exacerbating radiation-induced aberrant mitosis[J].Translational Oncology,2017,10(4):491-500.
[31]Barnard D,Diaz HB,Burke T,et al.LY2603618,a selective CHK1 inhibitor,enhances the anti-tumor effect of gemcitabine in xenograft tumor models[J].Investigational New Drugs,2016,34(1):49-60.
[32]Vincelette ND,Ding H,Huehls AM,et al.Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo[J].Scientific Reports,2019,9(1):3617.
[33]Preet R,Siddharth S,Satapathy SR,et al.Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade[J].Biochemical Pharmacology,2016,105(1):23-33.
[34]Hauge S,Naucke C,Hasvold G,et al.Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage+in S-phase due to distinct regulation of CDK activity and CDC45 loading[J].Oncotarget,2017,8(7):10966-10979.
[35]Booth L,Roberts J,Poklepovic A,et al.The Chk1 inhibitor,SRA737,synergizes with niraparib to kill cancer cells via multiple cell death pathways[A]//Proceedings of the American Association for Cancer Research Annual Meeting[C].2018.
[36]Yin Y,Shen Q,Zhang P,et al.Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer[J].American Journal of Cancer Research,2017,7(3):473.